A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial

BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive, treatment resistant neoplasm. The current treatment, consisting of antifolate and platinum-based chemotherapy, improves the median overall survival with only 3 months. Adjuvant bevacizumab generates an additional 2 months survival be...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Transl Lung Cancer Res
Autori principali: Belderbos, Robert A., Baas, Paul, Berardi, Rossana, Cornelissen, Robin, Fennell, Dean A., van Meerbeeck, Jan P., Scherpereel, Arnaud, Vroman, Heleen, Aerts, Joachim G. J. V.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AME Publishing Company 2019
Soggetti:
Study Protocol
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6626859/
https://ncbi.nlm.nih.gov/pubmed/31367541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2019.05.05
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi